TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms Roman R Schimmer,Larisa V Kovtonyuk,Nancy Klemm,Jonas Fullin,Sebastian M Stolz,Jan Mueller,Francisco Caiado,Kari J Kurppa,Benjamin L Ebert,Markus G Manz,Steffen BoettcherBlood Advances(2022)引用 5|浏览16暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要